Strategy Asset Managers’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-219,990
| Closed | -$8.07M | – | 303 |
|
|
2024
Q2 | $8.07M | Buy |
219,990
+210,341
| +2,180% | +$5.79M | 1.79% | 16 |
|
|
2024
Q1 | $268K | Buy |
9,649
+153
| +2% | +$4.25K | 0.06% | 204 |
|
|
2023
Q4 | $273K | Sell |
9,496
-182,228
| -95% | -$5.51M | 0.06% | 191 |
|
|
2023
Q3 | $6.36M | Sell |
191,724
-28,266
| -13% | -$1,000K | 1.66% | 19 |
|
|
2023
Q2 | $8.07M | Buy |
219,990
+15,697
| +8% | +$611K | 1.79% | 16 |
|
|
2023
Q1 | $8.34M | Buy |
204,293
+7,934
| +4% | +$343K | 2.03% | 13 |
|
|
2022
Q4 | $10.1M | Sell |
196,359
-2,921
| -1% | -$140K | 2.56% | 4 |
|
|
2022
Q3 | $8.72M | Sell |
199,280
-2,509
| -1% | -$122K | 2.37% | 6 |
|
|
2022
Q2 | $10.6M | Buy |
201,789
+381
| +0.2% | +$19.4K | 3.26% | 4 |
|
|
2022
Q1 | $10.4M | Buy |
201,408
+5,536
| +3% | +$287K | 2.26% | 9 |
|
|
2021
Q4 | $11.6M | Sell |
195,872
-1,103
| -0.6% | -$54.6K | 3% | 3 |
|
|
2021
Q3 | $8.47M | Sell |
196,975
-10,151
| -5% | -$450K | 1.88% | 13 |
|
|
2021
Q2 | $8.11M | Buy |
207,126
+398
| +0.2% | +$15.5K | 1.72% | 17 |
|
|
2021
Q1 | $7.49M | Sell |
206,728
-5,859
| -3% | -$208K | 1.72% | 18 |
|
|
2020
Q4 | $7.83M | Sell |
212,587
-17,065
| -7% | -$626K | 1.87% | 15 |
|
|
2020
Q3 | $8M | Sell |
229,652
-11,258
| -5% | -$395K | 2.07% | 9 |
|
|
2020
Q2 | $7.47M | Sell |
240,910
-5,303
| -2% | -$180K | 2% | 14 |
|
|
2020
Q1 | $7.63M | Sell |
246,213
-19,480
| -7% | -$664K | 2.46% | 10 |
|
|
2019
Q4 | $9.88M | Sell |
265,693
-8,253
| -3% | -$294K | 2.44% | 11 |
|
|
2019
Q3 | $9.34M | Sell |
273,946
-10,773
| -4% | -$392K | 2.78% | 14 |
|
|
2019
Q2 | $11.7M | Sell |
284,719
-4,873
| -2% | -$194K | 3.31% | 6 |
|
|
2019
Q1 | $11.7M | Sell |
289,592
-7,283
| -2% | -$292K | 2.62% | 6 |
|
|
2018
Q4 | $12.3M | Sell |
296,875
-12,825
| -4% | -$532K | 3% | 3 |
|
|
2018
Q3 | $12.9M | Sell |
309,700
-7,078
| -2% | -$272K | 2.63% | 4 |
|
|
2018
Q2 | $10.9M | Sell |
316,778
-4,446
| -1% | -$152K | 2.3% | 9 |
|
|
2018
Q1 | $10.8M | Sell |
321,224
-8,672
| -3% | -$298K | 2.34% | 13 |
|
|
2017
Q4 | $11.3M | Buy |
329,896
+2,089
| +0.6% | +$71.2K | 2.22% | 15 |
|
|
2017
Q3 | $11.1M | Sell |
327,807
-5,756
| -2% | -$185K | 2.27% | 15 |
|
|
2017
Q2 | $10.6M | Buy |
333,563
+19,187
| +6% | +$605K | 2.19% | 15 |
|
|
2017
Q1 | $10.2M | Sell |
314,376
-816
| -0.3% | -$25.7K | 2.22% | 14 |
|
|
2016
Q4 | $9.36M | Buy |
315,192
+465
| +0.1% | +$14.2K | 2.05% | 17 |
|
|
2016
Q3 | $10.1M | Buy |
314,727
+754
| +0.2% | +$25.2K | 2.27% | 12 |
|
|
2016
Q2 | $10.5M | Buy |
313,973
+246,738
| +367% | +$7.87M | 2.38% | 6 |
|
|
2016
Q1 | $1.89M | Buy |
67,235
+7,665
| +13% | +$219K | 0.43% | 81 |
|
|
2015
Q4 | $1.82M | Buy |
59,570
+604
| +1% | +$19K | 0.42% | 77 |
|
|
2015
Q3 | $1.76M | Buy |
58,966
+2,121
| +4% | +$68K | 0.42% | 75 |
|
|
2015
Q2 | $1.81M | Buy |
56,845
+3,631
| +7% | +$118K | 0.4% | 71 |
|
|
2015
Q1 | $1.76M | Buy |
53,214
+2,369
| +5% | +$75.3K | 0.38% | 76 |
|
|
2014
Q4 | $1.5M | Buy |
50,845
+2,352
| +5% | +$67.4K | 0.32% | 72 |
|
|
2014
Q3 | $1.36M | Buy |
48,493
+9,408
| +24% | +$264K | 0.3% | 75 |
|
|
2014
Q2 | $1.1M | Buy |
39,085
+285
| +0.7% | +$8.12K | 0.23% | 71 |
|
|
2014
Q1 | $1.18M | Sell |
38,800
-1,882
| -5% | -$56.1K | 0.25% | 70 |
|
|
2013
Q4 | $1.18M | Buy |
40,682
+2,926
| +8% | +$85.2K | 0.26% | 73 |
|
|
2013
Q3 | $1.03M | Sell |
37,756
-104,864
| -74% | -$2.85M | 0.24% | 75 |
|
|
2013
Q2 | $3.79M | Buy |
+142,620
| New | +$3.94M | 0.9% | 32 |
|
Other funds holding PFE
Strategy Asset Managers's PFE Position: Q3 2024 in Review
Strategy Asset Managers sold out of Pfizer (PFE) in Q3 2024, closing a stake of 219,990 shares — an estimated $8.07M sold.
Strategy Asset Managers first reported a position in PFE in Q2 2013 and held it in 45 quarters. The position peaked at $12.9M in Q3 2018. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- Strategy Asset Managers reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
- Strategy Asset Managers sold 219,990 Pfizer shares in Q3 2024, an estimated $8.07M.
- Strategy Asset Managers first reported a position in Pfizer in Q2 2013 and held it in 45 quarters.
- Strategy Asset Managers's Pfizer position peaked at $12.9M in Q3 2018.
- 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on Strategy Asset Managers's 13F filing for Q3 2024, filed 8 Nov 2024.